Details of the Drug

General Information of Drug (ID: DM3ICO6)

Drug Name
JNJ-74494550
Synonyms Cusatuzumab
Indication
Disease Entry ICD 11 Status REF
Myelodysplastic syndrome 2A37 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
RR5U4UFJ8L
DrugBank ID
DB15100
TTD ID
D6Q5MG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD70 antigen (CD27-L) TTNCIE0 CD70_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Myelodysplastic syndrome
ICD Disease Classification 2A37
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD70 antigen (CD27-L) DTT CD70 1.53E-09 0.76 2.84
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04264806) A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT). U.S. National Institutes of Health.
2 Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.